Oncology Central

ASCO18: Taselisib, combined with Faslodex®, halts growth of advanced breast cancer

Results from a Phase lll clinical trial, assessing the effectiveness of a new targeted drug, taselisib, demonstrated promising results against advanced breast cancer when combined with standard hormone therapy fulvestrant (Faslodex®).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.